Skip to main content
PMC home page
Clinical Microbiology Reviews logoLink to Clinical Microbiology Reviews
. 1988 Apr;1(2):187–217. doi: 10.1128/cmr.1.2.187

Overview of medically important antifungal azole derivatives.

R A Fromtling 1
PMCID: PMC358042  PMID: 3069196

Abstract

Fungal infections are a major burden to the health and welfare of modern humans. They range from simply cosmetic, non-life-threatening skin infections to severe, systemic infections that may lead to significant debilitation or death. The selection of chemotherapeutic agents useful for the treatment of fungal infections is small. In this overview, a major chemical group with antifungal activity, the azole derivatives, is examined. Included are historical and state of the art information on the in vitro activity, experimental in vivo activity, mode of action, pharmacokinetics, clinical studies, and uses and adverse reactions of imidazoles currently marketed (clotrimazole, miconazole, econazole, ketoconazole, bifonazole, butoconazole, croconazole, fenticonazole, isoconazole, oxiconazole, sulconazole, and tioconazole) and under development (aliconazole and omoconazole), as well as triazoles currently marketed (terconazole) and under development (fluconazole, itraconazole, vibunazole, alteconazole, and ICI 195,739).

Full text

PDF
188

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abruzzo G. K., Giltinan D. M., Capizzi T. P., Fromtling R. A. Influence of six antifungal agents on the chemiluminescence response of mouse spleen cells. Antimicrob Agents Chemother. 1986 Apr;29(4):602–607. doi: 10.1128/aac.29.4.602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ackerbauer H., Meingassner J. G., Mieth H. Experimentelle renale Infektionen der Maus mit Aspergillus fumigatus: Ein chemotherapeutisches Modell einer Organmykose. Mykosen. 1985 May;28(5):244–250. doi: 10.1111/j.1439-0507.1985.tb02124.x. [DOI] [PubMed] [Google Scholar]
  3. Alford R. H., Cartwright B. B. Comparison of ketoconazole and amphotericin B in interference with thymidine uptake by and blastogenesis of lymphocytes stimulated with Histoplasma capsulatum antigens. Antimicrob Agents Chemother. 1983 Oct;24(4):575–578. doi: 10.1128/aac.24.4.575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Anséhn S., Nilsson L. Direct membrane-damaging effect of ketoconazole and tioconazole on Candida albicans demonstrated by bioluminescent assay of ATP. Antimicrob Agents Chemother. 1984 Jul;26(1):22–25. doi: 10.1128/aac.26.1.22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Artner J., Fuchs G. Open studies of the efficacy, tolerance, systemic absorption and vaginal persistence following a single application of tioconazole ointment in the treatment of patients with vaginal candidiasis. Gynakol Rundsch. 1983;23 (Suppl 1):12–19. doi: 10.1159/000269564. [DOI] [PubMed] [Google Scholar]
  6. Athow-Frost T. A., Freeman K., Mann T. A., Marks R., Vollum D., Warin A. P. Clinical evaluation of fenticonazole cream in cutaneous fungal infections: a comparison with miconazole cream. Curr Med Res Opin. 1986;10(2):107–116. doi: 10.1185/03007998609110427. [DOI] [PubMed] [Google Scholar]
  7. Balbi C., D'Ajello M., Balbi G. C. Treatment with ketoconazole in diabetic patients with vaginal candidiasis. Drugs Exp Clin Res. 1986;12(5):413–414. [PubMed] [Google Scholar]
  8. Barug D., de Groot C. Microscopic studies of Candida albicans and Torulopsis glabrata after in vitro treatment with bifonazole. Freeze fracture electron microscopy. Arzneimittelforschung. 1983;33(4):538–545. [PubMed] [Google Scholar]
  9. Bastide M., Jouvert S., Bastide J. M. A comparison of the effects of several antifungal imidazole derivatives and polyenes on Candida albicans: an ultrastructural study by scanning electron microscopy. Can J Microbiol. 1982 Oct;28(10):1119–1126. doi: 10.1139/m82-166. [DOI] [PubMed] [Google Scholar]
  10. Baxter J. G., Brass C., Schentag J. J., Slaughter R. L. Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. J Pharm Sci. 1986 May;75(5):443–447. doi: 10.1002/jps.2600750504. [DOI] [PubMed] [Google Scholar]
  11. Beggs W. H. Comparison of miconazole- and ketoconazole-induced release of K+ from Candida species. J Antimicrob Chemother. 1983 Apr;11(4):381–383. doi: 10.1093/jac/11.4.381. [DOI] [PubMed] [Google Scholar]
  12. Beggs W. H. Fungicidal activity of tioconazole in relation to growth phase of Candida albicans and Candida parapsilosis. Antimicrob Agents Chemother. 1984 Nov;26(5):699–701. doi: 10.1128/aac.26.5.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Beggs W. H., Hughes C. E. Exploitation of the direct cell damaging action of antifungal azoles. Diagn Microbiol Infect Dis. 1987 Jan;6(1):1–3. doi: 10.1016/0732-8893(87)90108-8. [DOI] [PubMed] [Google Scholar]
  14. Beggs W. H., Hughes C. E. Irrelevance of growth phase with respect to the Bay n 7133 and ICI 153,066 susceptibilities of Candida albicans. Diagn Microbiol Infect Dis. 1986 Jan;4(1):83–86. doi: 10.1016/0732-8893(86)90061-1. [DOI] [PubMed] [Google Scholar]
  15. Beggs W. H. Influence of growth phase on the susceptibility of Candida albicans to butoconazole, oxiconazole, and sulconazole. J Antimicrob Chemother. 1985 Sep;16(3):397–399. doi: 10.1093/jac/16.3.397. [DOI] [PubMed] [Google Scholar]
  16. Beggs W. H. Rapid fungicidal action of tioconazole and miconazole. Mycopathologia. 1987 Mar;97(3):187–188. doi: 10.1007/BF00437242. [DOI] [PubMed] [Google Scholar]
  17. Benijts G., Vignalli M., Kreysing W., Stettendorf S. Three-day therapy of vaginal candidiasis with clotrimazole vaginal tablets and econazole ovules: a multicentre comparative study. Curr Med Res Opin. 1980;7(1):55–61. doi: 10.1185/03007998009116516. [DOI] [PubMed] [Google Scholar]
  18. Bennett J. E., Remington J. S. Miconazole in cryptococcosis and systemic candidiasis: a word of caution. Ann Intern Med. 1981 May;94(5):708–709. doi: 10.7326/0003-4819-94-5-708. [DOI] [PubMed] [Google Scholar]
  19. Berg D., Regel E., Harenberg H. E., Plempel M. Bifonazole and clotrimazole. Their mode of action and the possible reason for the fungicidal behaviour of bifonazole. Arzneimittelforschung. 1984;34(2):139–146. [PubMed] [Google Scholar]
  20. Bergan T., Vangdal M. In vitro activity of antifungal agents against yeast species. Chemotherapy. 1983;29(2):104–110. doi: 10.1159/000238182. [DOI] [PubMed] [Google Scholar]
  21. Best T. R., Jenkins J. K., Murphy F. Y., Nicks S. A., Bussell K. L., Vesely D. L. Persistent adrenal insufficiency secondary to low-dose ketoconazole therapy. Am J Med. 1987 Mar 23;82(3 Spec No):676–680. doi: 10.1016/0002-9343(87)90123-9. [DOI] [PubMed] [Google Scholar]
  22. Botter A. A. Topical treatment of nail and skin infections with miconazole, a new broad-spectrum antimycotic. Mykosen. 1971 Apr 1;14(4):187–191. doi: 10.1111/j.1439-0507.1971.tb03028.x. [DOI] [PubMed] [Google Scholar]
  23. Bradbeer C. S., Mayhew S. R., Barlow D. Butoconazole and miconazole in treating vaginal candidiasis. Genitourin Med. 1985 Aug;61(4):270–272. doi: 10.1136/sti.61.4.270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Brass C., Galgiani J. N., Blaschke T. F., Defelice R., O'Reilly R. A., Stevens D. A. Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother. 1982 Jan;21(1):151–158. doi: 10.1128/aac.21.1.151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Brewster E., Preti P. M., Ruffmann R., Studd J. Effect of fenticonazole in vaginal candidiasis: a double-blind clinical trial versus clotrimazole. J Int Med Res. 1986;14(6):306–310. doi: 10.1177/030006058601400604. [DOI] [PubMed] [Google Scholar]
  26. Brown D., Jr, Henzl M. R., LePage M. E., Tsao L. L., Izu A. E., Walker K. A., Adamson G. D., Droegmuller W. Butoconazole vaginal cream in the treatment of vulvovaginal candidiasis. Comparison with miconazole nitrate and placebo. J Reprod Med. 1986 Nov;31(11):1045–1048. [PubMed] [Google Scholar]
  27. Brugmans J. P., Thienpont D. C., van Wijngaarden I., Vanparijs O. F., Schuermans V. L., Lauwers H. L. Mebendazole in enterobiasis. Radiochemical and pilot clinical study in 1,278 subjects. JAMA. 1971 Jul 19;217(3):313–316. [PubMed] [Google Scholar]
  28. Bullock W. E., Deepe G. S., Jr Medical mycology in crisis. J Lab Clin Med. 1983 Nov;102(5):685–693. [PubMed] [Google Scholar]
  29. Burgess M. A., Bodey G. P. Clotrimazole (Bay b 5097): in vitro and clinical pharmacological studies. Antimicrob Agents Chemother. 1972 Dec;2(6):423–426. doi: 10.1128/aac.2.6.423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Cacciaglia G. B., Tenczar A. J., Kanat I. O. Pharmacologic review: a review of the literature of ketoconazole therapy in the treatment of tinea pedis and onychomycosis. J Foot Surg. 1984 Sep-Oct;23(5):420–423. [PubMed] [Google Scholar]
  31. Cartwright R. Y. Clotrimazole in the treatment of acute and "resistant' vaginal candidiasis. Postgrad Med J. 1974 Jul;50 (Suppl 1):90–92. [PubMed] [Google Scholar]
  32. Cauwenbergh G. Prophylaxis of mycotic infections in immunocompromised patients: a review of 27 reports and publications. Drugs Exp Clin Res. 1986;12(5):419–427. [PubMed] [Google Scholar]
  33. Chandler F. W. Pathology of the mycoses in patients with the acquired immunodeficiency syndrome (AIDS). Curr Top Med Mycol. 1985;1:1–23. doi: 10.1007/978-1-4613-9547-8_1. [DOI] [PubMed] [Google Scholar]
  34. Clayton Y. M., Connor B. L. Comparison of clotrimazole cream, Whitfield's ointment and Nystatin ointment for the topical treatment of ringworm infections, pityriasis versicolor, erythrasma and candidiasis. Br J Dermatol. 1973 Sep;89(3):297–303. doi: 10.1111/j.1365-2133.1973.tb02978.x. [DOI] [PubMed] [Google Scholar]
  35. Clissold S. P., Heel R. C. Tioconazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses. Drugs. 1986 Jan;31(1):29–51. doi: 10.2165/00003495-198631010-00003. [DOI] [PubMed] [Google Scholar]
  36. Cope J. E. Mode of action of miconazole on Candida albicans: effect on growth, viability and K+ release. J Gen Microbiol. 1980 Jul;119(1):245–251. doi: 10.1099/00221287-119-1-245. [DOI] [PubMed] [Google Scholar]
  37. Cornelis G., Laroche Y., Balligand G., Sory M. P., Wauters G. Yersinia enterocolitica, a primary model for bacterial invasiveness. Rev Infect Dis. 1987 Jan-Feb;9(1):64–87. doi: 10.1093/clinids/9.1.64. [DOI] [PubMed] [Google Scholar]
  38. Cornelis G., Laroche Y., Balligand G., Sory M. P., Wauters G. Yersinia enterocolitica, a primary model for bacterial invasiveness. Rev Infect Dis. 1987 Jan-Feb;9(1):64–87. doi: 10.1093/clinids/9.1.64. [DOI] [PubMed] [Google Scholar]
  39. Corrado M. L., Kramer M., Cummings M., Eng R. H. Susceptibility of dermatiaceous fungi to amphotericin B, miconazole, ketoconazole, flucytosine and rifampin alone and in combination. Sabouraudia. 1982 Jun;20(2):109–113. doi: 10.1080/00362178285380181. [DOI] [PubMed] [Google Scholar]
  40. Costa A. L. "In vitro" antimycotic activity of fenticonazole (Rec 15/1476). Mykosen. 1982 Jan;25(1):47–52. [PubMed] [Google Scholar]
  41. Costa A. L., Valenti A., Veronese M. Study of the morphofunctional alterations produced by fenticonazole on strains of Candida albicans, using the scanning electron microscope (S.E.M). Mykosen. 1984 Jan;27(1):29–35. doi: 10.1111/j.1439-0507.1984.tb01979.x. [DOI] [PubMed] [Google Scholar]
  42. Cusumano V., Costa A. L., Veronese M. Evaluation of the antifungal activity of fenticonazole on strains of Candida albicans on cellular lines. Mykosen. 1985 May;28(5):238–243. doi: 10.1111/j.1439-0507.1985.tb02123.x. [DOI] [PubMed] [Google Scholar]
  43. D'Arcy P. F., Scott E. M. Antifungal agents. Prog Drug Res. 1978;22:93–147. doi: 10.1007/978-3-0348-7102-0_3. [DOI] [PubMed] [Google Scholar]
  44. Daneshmend T. K. Systemic absorption of miconazole from the vagina. J Antimicrob Chemother. 1986 Oct;18(4):507–511. doi: 10.1093/jac/18.4.507. [DOI] [PubMed] [Google Scholar]
  45. Daneshmend T. K., Warnock D. W., Ene M. D., Johnson E. M., Potten M. R., Richardson M. D., Williamson P. J. Influence of food on the pharmacokinetics of ketoconazole. Antimicrob Agents Chemother. 1984 Jan;25(1):1–3. doi: 10.1128/aac.25.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. De Nollin S., Van Belle H., Goossens F., Thone F., Borgers M. Cytochemical and biochemical studies of yeasts after in vitro exposure to miconazole. Antimicrob Agents Chemother. 1977 Mar;11(3):500–513. doi: 10.1128/aac.11.3.500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. DeFelice R., Johnson D. G., Galgiani J. N. Gynecomastia with ketoconazole. Antimicrob Agents Chemother. 1981 Jun;19(6):1073–1074. doi: 10.1128/aac.19.6.1073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Del Palacio-Hernanz A., Sanz-Sanz F., Rodriquez-Noriega A. Double-blind investigation of R-42470 (terconazole cream 0.4%) and clotrimazole (cream 1%) for the topical treatment of mycotic vaginitis. Chemioterapia. 1984 Jun;3(3):192–195. [PubMed] [Google Scholar]
  49. Dieperink H., Møller J. Ketoconazole and cyclosporin. Lancet. 1982 Nov 27;2(8309):1217–1217. doi: 10.1016/s0140-6736(82)91231-4. [DOI] [PubMed] [Google Scholar]
  50. Dismukes W. E., Stamm A. M., Graybill J. R., Craven P. C., Stevens D. A., Stiller R. L., Sarosi G. A., Medoff G., Gregg C. R., Gallis H. A. Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. Ann Intern Med. 1983 Jan;98(1):13–20. doi: 10.7326/0003-4819-98-1-13. [DOI] [PubMed] [Google Scholar]
  51. Dixon D. M., Polak A. In vitro and in vivo drug studies with three agents of central nervous system phaeohyphomycosis. Chemotherapy. 1987;33(2):129–140. doi: 10.1159/000238485. [DOI] [PubMed] [Google Scholar]
  52. Dixon D., Shadomy S., Shadomy H. J., Espinel-Ingroff A., Kerkering T. M. Comparison of the in vitro antifungal activities of miconazole and a new imidazole, R41,400. J Infect Dis. 1978 Aug;138(2):245–248. doi: 10.1093/infdis/138.2.245. [DOI] [PubMed] [Google Scholar]
  53. Droegemueller W., Adamson D. G., Brown D., Cibley L., Fleury F., LePage M. E., Henzl M. R. Three-day treatment with butoconazole nitrate for vulvovaginal candidiasis. Obstet Gynecol. 1984 Oct;64(4):530–534. [PubMed] [Google Scholar]
  54. Duarte P. A., Chow C. C., Simmons F., Ruskin J. Fatal hepatitis associated with ketoconazole therapy. Arch Intern Med. 1984 May;144(5):1069–1070. [PubMed] [Google Scholar]
  55. Dupont B., Drouhet E. Cryptococcal meningitis and fluconazole. Ann Intern Med. 1987 May;106(5):778–778. doi: 10.7326/0003-4819-106-5-778_2. [DOI] [PubMed] [Google Scholar]
  56. Espinel-Ingroff A., Shadomy S., Fisher J. F. Bioassay for miconazole. Antimicrob Agents Chemother. 1977 Feb;11(2):365–368. doi: 10.1128/aac.11.2.365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Espinel-Ingroff A., Shadomy S., Gebhart R. J. In vitro studies with R 51,211 (itraconazole). Antimicrob Agents Chemother. 1984 Jul;26(1):5–9. doi: 10.1128/aac.26.1.5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Fainstein V., Bodey G. P., Elting L., Maksymiuk A., Keating M., McCredie K. B. Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients. Antimicrob Agents Chemother. 1987 Jan;31(1):11–15. doi: 10.1128/aac.31.1.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Farkas B., Simon N. Ergebnisse einer Vergleichsstudie mit einem oral und einem lokal zu applizierenden Antimykotikum bei Vaginalmykosen. Mykosen. 1984 Nov;27(11):554–561. [PubMed] [Google Scholar]
  60. Feldman D. Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr Rev. 1986 Nov;7(4):409–420. doi: 10.1210/edrv-7-4-409. [DOI] [PubMed] [Google Scholar]
  61. Feldman R. M., Singer C. Noncardiogenic pulmonary edema and pulmonary fibrosis in falciparum malaria. Rev Infect Dis. 1987 Jan-Feb;9(1):134–139. doi: 10.1093/clinids/9.1.134. [DOI] [PubMed] [Google Scholar]
  62. Feldman R. M., Singer C. Noncardiogenic pulmonary edema and pulmonary fibrosis in falciparum malaria. Rev Infect Dis. 1987 Jan-Feb;9(1):134–139. doi: 10.1093/clinids/9.1.134. [DOI] [PubMed] [Google Scholar]
  63. Finzi A., Fioroni A., Monici Preti P., Mounari M. A double blind evaluation of fenticonazole cream 2% and clotrimazole cream 1% in dermatomycoses. Mykosen. 1986 Jan;29(1):41–44. [PubMed] [Google Scholar]
  64. Fraser D. W., Ward J. I., Ajello L., Plikaytis B. D. Aspergillosis and other systemic mycoses. The growing problem. JAMA. 1979 Oct 12;242(15):1631–1635. [PubMed] [Google Scholar]
  65. Fromtling R. A., Abruzzo G. K., Bulmer G. S. Cryptococcus neoformans: comparisons of in vitro antifungal susceptibilities of serotypes AD and BC. Mycopathologia. 1986 Apr;94(1):27–30. doi: 10.1007/BF00437258. [DOI] [PubMed] [Google Scholar]
  66. Fromtling R. A., Yu H. P., Shadomy S. In vitro antifungal activities of Bay n 7133 and Bay L 9139, two new orally absorbed antifungal imidazole derivatives, against pathogenic yeasts. Mycopathologia. 1984 Apr 30;86(1):45–50. doi: 10.1007/BF00437228. [DOI] [PubMed] [Google Scholar]
  67. Fromtling R. A., Yu H. P., Shadomy S. In-vitro inhibitory activities of 2 new orally absorbable imidazole derivatives: BAY n 7133 and BAY 1 9139. Sabouraudia. 1983 Sep;21(3):179–184. doi: 10.1080/00362178385380291. [DOI] [PubMed] [Google Scholar]
  68. Galgiani J. N. Ketoconazole in the treatment of coccidioidomycosis. Drugs. 1983 Oct;26(4):355–363. doi: 10.2165/00003495-198326040-00005. [DOI] [PubMed] [Google Scholar]
  69. Gan V. N., Petruska M., Ginsburg C. M. Epidemiology and treatment of tinea capitis: ketoconazole vs. griseofulvin. Pediatr Infect Dis J. 1987 Jan;6(1):46–49. doi: 10.1097/00006454-198701000-00012. [DOI] [PubMed] [Google Scholar]
  70. Gebhart R. J., Espinel-Ingroff A., Shadomy S. In vitro susceptibility studies with oxiconazole (Ro 13-8996). Chemotherapy. 1984;30(4):244–247. doi: 10.1159/000238275. [DOI] [PubMed] [Google Scholar]
  71. Georgopapadakou N. H., Dix B. A., Smith S. A., Freudenberger J., Funke P. T. Effect of antifungal agents on lipid biosynthesis and membrane integrity in Candida albicans. Antimicrob Agents Chemother. 1987 Jan;31(1):46–51. doi: 10.1128/aac.31.1.46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Gip L. Comparison of oxiconazole (Ro 13-8996) and econazole in dermatomycoses. Mykosen. 1984 Jun;27(6):295, 298-302. doi: 10.1111/j.1439-0507.1984.tb02033.x. [DOI] [PubMed] [Google Scholar]
  73. Gip L., Forsström S. A double-blind parallel study of sulconazole nitrate 1% cream compared with miconazole nitrate 2% cream in dermatophytoses. Mykosen. 1983 May;26(5):231–241. [PubMed] [Google Scholar]
  74. Godefroi E. F., Heeres J., Van Cutsem J., Janssen P. A. The preparation and antimycotic properties of derivatives of 1-phenethylimidazole. J Med Chem. 1969 Sep;12(5):784–791. doi: 10.1021/jm00305a014. [DOI] [PubMed] [Google Scholar]
  75. Gouveia D. C., Jones da Silva C. Oxiconazole in the treatment of vaginal candidiasis: single dose versus 3-day treatment with econazole. Pharmatherapeutica. 1984;3(10):682–685. [PubMed] [Google Scholar]
  76. Graybill J. R., Ahrens J. Itraconazole treatment of murine aspergillosis. Sabouraudia. 1985 Jun;23(3):219–223. doi: 10.1080/00362178585380321. [DOI] [PubMed] [Google Scholar]
  77. Graybill J. R., Kaster S. R., Drutz D. J. Comparative activities of Bay n7133, ICI 153,066, and ketoconazole in murine cryptococcosis. Antimicrob Agents Chemother. 1983 Dec;24(6):829–834. doi: 10.1128/aac.24.6.829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Graybill J. R., Kaster S. R., Drutz D. J. Treatment of experimental murine aspergillosis with BAY n7133. J Infect Dis. 1983 Nov;148(5):898–906. doi: 10.1093/infdis/148.5.898. [DOI] [PubMed] [Google Scholar]
  79. Graybill J. R., Levine H. B. Successful treatment of cryptococcal meningitis with intraventricular miconazole. Arch Intern Med. 1978 May;138(5):814–816. [PubMed] [Google Scholar]
  80. Graybill J. R., Sun S. H., Ahrens J. Treatment of murine coccidioidal meningitis with fluconazole (UK 49,858). J Med Vet Mycol. 1986 Apr;24(2):113–119. doi: 10.1080/02681218680000171. [DOI] [PubMed] [Google Scholar]
  81. Green C. A., Farr P. M., Shuster S. Treatment of seborrhoeic dermatitis with ketoconazole: II. Response of seborrhoeic dermatitis of the face, scalp and trunk to topical ketoconazole. Br J Dermatol. 1987 Feb;116(2):217–221. doi: 10.1111/j.1365-2133.1987.tb05815.x. [DOI] [PubMed] [Google Scholar]
  82. Greene N. B., Baughman R. P., Kim C. K., Roselle G. A. Failure of ketoconazole in an immunosuppressed patient with pulmonary blastomycosis. Chest. 1985 Oct;88(4):640–641. doi: 10.1378/chest.88.4.640. [DOI] [PubMed] [Google Scholar]
  83. Grigoriu D., Grigoriu A. Double-blind comparison of the efficacy, toleration and safety of tioconazole base 1% and econazole nitrate 1% creams in the treatment of patients with fungal infections of the skin or erythrasma. Dermatologica. 1983;166 (Suppl 1):8–13. doi: 10.1159/000249908. [DOI] [PubMed] [Google Scholar]
  84. Guaschino S., Michelone G., Stola E., Lombardi G., Spinillo A., Viale P. Mycotic vaginitis in pregnancy: a double evaluation of the susceptibility to the main antimycotic drugs of isolated species. Biol Res Pregnancy Perinatol. 1986;7(1):20–22. [PubMed] [Google Scholar]
  85. HERRLING S., SOUS H., KRUEPE W., OSTERLOH G., MUECKTER H. [Experimental studies on a new combination effective against fungi]. Arzneimittelforschung. 1959 Aug;9:489–494. [PubMed] [Google Scholar]
  86. Hansen R. M., Reinerio N., Sohnle P. G., Abrams R. A., Ritch P. S., Libnoch J. A., Anderson T. Ketoconazole in the prevention of candidiasis in patients with cancer. A prospective, randomized, controlled, double-blind study. Arch Intern Med. 1987 Apr;147(4):710–712. [PubMed] [Google Scholar]
  87. Hay R. J., Mackie R. M., Clayton Y. M. Tioconazole nail solution--an open study of its efficacy in onychomycosis. Clin Exp Dermatol. 1985 Mar;10(2):111–115. doi: 10.1111/j.1365-2230.1985.tb00537.x. [DOI] [PubMed] [Google Scholar]
  88. Heel R. C., Brogden R. N., Carmine A., Morley P. A., Speight T. M., Avery G. S. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs. 1982 Jan-Feb;23(1-2):1–36. doi: 10.2165/00003495-198223010-00001. [DOI] [PubMed] [Google Scholar]
  89. Heel R. C., Brogden R. N., Pakes G. E., Speight T. M., Avery G. S. Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections. Drugs. 1980 Jan;19(1):7–30. doi: 10.2165/00003495-198019010-00002. [DOI] [PubMed] [Google Scholar]
  90. Heeres J., Backx L. J., Mostmans J. H., Van Cutsem J. Antimycotic imidazoles. part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent. J Med Chem. 1979 Aug;22(8):1003–1005. doi: 10.1021/jm00194a023. [DOI] [PubMed] [Google Scholar]
  91. Heeres J., Backx L. J., Van Cutsem J. Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones. J Med Chem. 1984 Jul;27(7):894–900. doi: 10.1021/jm00373a015. [DOI] [PubMed] [Google Scholar]
  92. Heeres J., Hendrickx R., Van Cutsem J. Antimycotic azoles. 6. Synthesis and antifungal properties of terconazole, a novel triazole ketal. J Med Chem. 1983 Apr;26(4):611–613. doi: 10.1021/jm00358a032. [DOI] [PubMed] [Google Scholar]
  93. Henderson J. T., Neilson W., Wilson A. B., Jevons S. Tioconazole in the treatment of vaginal candidiasis. An international clinical research program. Gynakol Rundsch. 1983;23 (Suppl 1):42–60. doi: 10.1159/000269570. [DOI] [PubMed] [Google Scholar]
  94. Hoeprich P. D., Goldstein E. Miconazole therapy for coccidioidomycosis. JAMA. 1974 Nov 25;230(8):1153–1157. [PubMed] [Google Scholar]
  95. Hoeprich P. D., Merry J. M. Activity of BAY n 7133 and BAY 1 9139 in vitro and in experimental murine coccidioidomycosis. Eur J Clin Microbiol. 1985 Aug;4(4):400–403. doi: 10.1007/BF02148692. [DOI] [PubMed] [Google Scholar]
  96. Hoeprich P. D., Merry J. M. In vitro activities of two new antifungal azoles. Antimicrob Agents Chemother. 1984 Mar;25(3):339–341. doi: 10.1128/aac.25.3.339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Hoeprich P. D., Merry J. M. Influence of culture medium on susceptibility testing with BAY n 7133 and ketoconazole. J Clin Microbiol. 1986 Aug;24(2):269–271. doi: 10.1128/jcm.24.2.269-271.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. Holt R. J., Newman R. L. Laboratory assessment of the antimycotic drug clotrimazole. J Clin Pathol. 1972 Dec;25(12):1089–1097. doi: 10.1136/jcp.25.12.1089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Houang E. T., Lawrence A. G. Systemic absorption and persistence of tioconazole in vaginal fluid after insertion of a single 300-mg tioconazole ovule. Antimicrob Agents Chemother. 1985 Jun;27(6):964–965. doi: 10.1128/aac.27.6.964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Huang Y. C., Colaizzi J. L., Bierman R. H., Woestenborghs R., Heykants J. Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrob Agents Chemother. 1986 Aug;30(2):206–210. doi: 10.1128/aac.30.2.206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Hughes C. E., Beggs W. H. Action of fluconazole (UK-49,858) in relation to other systemic antifungal azoles. J Antimicrob Chemother. 1987 Feb;19(2):171–174. doi: 10.1093/jac/19.2.171. [DOI] [PubMed] [Google Scholar]
  102. Hume A. L., Kerkering T. M. Ketoconazole. Drug Intell Clin Pharm. 1983 Mar;17(3):169–174. doi: 10.1177/106002808301700301. [DOI] [PubMed] [Google Scholar]
  103. Humphrey M. J., Jevons S., Tarbit M. H. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother. 1985 Nov;28(5):648–653. doi: 10.1128/aac.28.5.648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Hussain Qadri S. M., Flournoy D. J., Qadri S. G., Ramirez E. G. Susceptibility of clinical isolates of yeasts to anti-fungal agents. Mycopathologia. 1986 Sep;95(3):183–187. doi: 10.1007/BF00437125. [DOI] [PubMed] [Google Scholar]
  105. Höffken G., Lode H., Kessler H. J. Einfluss von Doxycyclin und Isoconazolnitrat auf die intestinale Pilzflora des Menschen. Arzneimittelforschung. 1983;33(2):273–276. [PubMed] [Google Scholar]
  106. Ishibashi Y., Matsumoto Y. Intravenous miconazole therapy for experimental keratomycosis in rabbits. Sabouraudia. 1985 Feb;23(1):55–61. doi: 10.1080/00362178585380091. [DOI] [PubMed] [Google Scholar]
  107. Jacobson J. B., Hajman A. J., Wiese J., Gandrup P., Forsström S. A new vaginal antifungal agent--butoconazole nitrate. Acta Obstet Gynecol Scand. 1985;64(3):241–244. doi: 10.3109/00016348509155121. [DOI] [PubMed] [Google Scholar]
  108. Janssen P. A., Symoens J. E. Hepatic reactions during ketoconazole treatment. Am J Med. 1983 Jan 24;74(1B):80–85. doi: 10.1016/0002-9343(83)90519-3. [DOI] [PubMed] [Google Scholar]
  109. Jevons S., Gymer G. E., Brammer K. W., Cox D. A., Leeming M. R. Antifungal activity of tioconazole (UK-20,349), a new imidazole derivative. Antimicrob Agents Chemother. 1979 Apr;15(4):597–602. doi: 10.1128/aac.15.4.597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  110. Jordan W. M., Bodey G. P., Rodriguez V., Ketchel S. J., Henney J. Miconazole therapy for treatment of fungal infections in cancer patients. Antimicrob Agents Chemother. 1979 Dec;16(6):792–797. doi: 10.1128/aac.16.6.792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  111. Kashin P., Phyfferoen M. C., Gibbs D. L. A comparative study of once versus twice daily treatment of superficial dermatophyte and yeast infections with tioconazole (1%) cream. J Int Med Res. 1985;13(2):88–95. doi: 10.1177/030006058501300203. [DOI] [PubMed] [Google Scholar]
  112. Katz M. E., Cassileth P. A. Disseminated candidiasis in a patient with acute leukemia. Successful treatment with miconazole. JAMA. 1977 Mar 14;237(11):1124–1125. [PubMed] [Google Scholar]
  113. Kessler H. J., Haude D., Schöbel C. Tierexperimentelle Prüfung des neuen Breitspektrum-Antimykotikums Isoconazolnitrat. Arzneimittelforschung. 1979;29(9):1352–1357. [PubMed] [Google Scholar]
  114. Kessler H. J. Mikrobiologische Untersuchungen mit Isoconazolnitrat, einem Breitspektrum-Antimykotikum aus der Gruppe der Imidazol-Derivate. Arzneimittelforschung. 1979;29(9):1344–1351. [PubMed] [Google Scholar]
  115. Kirkpatrick C. H., Alling D. W. Treatment of chronic oral candidiasis with clotrimazole troches. A controlled clinical trial. N Engl J Med. 1978 Nov 30;299(22):1201–1203. doi: 10.1056/NEJM197811302992201. [DOI] [PubMed] [Google Scholar]
  116. Kjaeldgaard A. Comparison of terconazole and clotrimazole vaginal tablets in the treatment of vulvovaginal candidosis. Pharmatherapeutica. 1986;4(8):525–531. [PubMed] [Google Scholar]
  117. Kobayashi G. S., Travis S., Medoff G. Comparison of the in vitro and in vivo activity of the bis-triazole derivative UK 49,858 with that of amphotericin B against Histoplasma capsulatum. Antimicrob Agents Chemother. 1986 Apr;29(4):660–662. doi: 10.1128/aac.29.4.660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  118. Kokoschka E. M., Niebauer G., Mounari M., Monici Preti P. Treatment of dermatomycoses with topical fenticonazole and econazole. Mykosen. 1986 Jan;29(1):45–50. [PubMed] [Google Scholar]
  119. Kowal J. The effect of ketoconazole on steroidogenesis in cultured mouse adrenal cortex tumor cells. Endocrinology. 1983 Apr;112(4):1541–1543. doi: 10.1210/endo-112-4-1541. [DOI] [PubMed] [Google Scholar]
  120. Kraemer F. B., Pont A. Inhibition of cholesterol synthesis by ketoconazole. Am J Med. 1986 Apr;80(4):616–622. doi: 10.1016/0002-9343(86)90816-8. [DOI] [PubMed] [Google Scholar]
  121. Lake-Bakaar G., Scheuer P. J., Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. Br Med J (Clin Res Ed) 1987 Feb 14;294(6569):419–422. doi: 10.1136/bmj.294.6569.419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  122. Lassus A., Forsström S. A double-blind parallel study comparing sulconazole with econazole in the treatment of dermatophytoses. Mykosen. 1984 Dec;27(12):592, 595-8. doi: 10.1111/j.1439-0507.1984.tb01994.x. [DOI] [PubMed] [Google Scholar]
  123. Lassus A., Forström S., Salo O. A double-blind comparison of sulconazole nitrate 1% cream with clotrimazole 1% cream in the treatment of dermatophytoses. Br J Dermatol. 1983 Feb;108(2):195–198. doi: 10.1111/j.1365-2133.1983.tb00062.x. [DOI] [PubMed] [Google Scholar]
  124. Latrille F., Perraud J., Stadler J., Monro A. M., Sutter B. C. Effects of tioconazole on parturition and serum levels of 17 beta-oestradiol, progesterone, LH and PRL in the rat. Biochem Pharmacol. 1987 Apr 1;36(7):1119–1124. doi: 10.1016/0006-2952(87)90422-9. [DOI] [PubMed] [Google Scholar]
  125. Lavrijsen K., Van Houdt J., Thijs D., Meuldermans W., Heykants J. Induction potential of antifungals containing an imidazole or triazole moiety. Miconazole and ketoconazole, but not itraconazole are able to induce hepatic drug metabolizing enzymes of male rats at high doses. Biochem Pharmacol. 1986 Jun 1;35(11):1867–1878. doi: 10.1016/0006-2952(86)90305-9. [DOI] [PubMed] [Google Scholar]
  126. Lefler E., Brummer E., McEwen J. G., Hoyos G. L., Restrepo A., Stevens D. A. Study of current and new drugs in a murine model of acute paracoccidioidomycosis. Am J Trop Med Hyg. 1985 Jan;34(1):134–140. doi: 10.4269/ajtmh.1985.34.134. [DOI] [PubMed] [Google Scholar]
  127. Lefler E., Brummer E., Perlman A. M., Stevens D. A. Activities of the modified polyene N-D-ornithyl amphotericin methyl ester and the azoles ICI 153066, Bay n 7133, and Bay l 9139 compared with those of amphotericin B and ketoconazole in the therapy of experimental blastomycosis. Antimicrob Agents Chemother. 1985 Mar;27(3):363–366. doi: 10.1128/aac.27.3.363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  128. Lefler E., Stevens D. A. Inhibition and killing of Candida albicans in vitro by five imidazoles in clinical use. Antimicrob Agents Chemother. 1984 Apr;25(4):450–454. doi: 10.1128/aac.25.4.450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  129. Lefler E., Stevens D. A. New azole compounds: vibunazole (Bay n7133) and Bay L9139, compared with ketoconazole in the therapy of systemic candidosis and in pharmacokinetic studies, in mice. J Antimicrob Chemother. 1985 Jan;15(1):69–75. doi: 10.1093/jac/15.1.69. [DOI] [PubMed] [Google Scholar]
  130. Levine H. B. A direct comparison of oral treatments with BAY-n-7133, BAY-1-9139 and ketoconazole in experimental murine coccidioidomycosis. Sabouraudia. 1984;22(1):37–46. doi: 10.1080/00362178485380071. [DOI] [PubMed] [Google Scholar]
  131. Levine H. B. R34000, a dioxolane imidazole in the therapy for experimental coccidioidomycosis. Comparison with miconazole and econazole. Chest. 1976 Dec;70(6):755–759. doi: 10.1378/chest.70.6.755. [DOI] [PubMed] [Google Scholar]
  132. Levine H. B., Stevens D. A., Cobb J. M., Gebhardt A. E. Miconazole in coccidioidomycosis. I. Assays of activity in mice and in vitro. J Infect Dis. 1975 Oct;132(4):407–414. doi: 10.1093/infdis/132.4.407. [DOI] [PubMed] [Google Scholar]
  133. Lewis J. H., Zimmerman H. J., Benson G. D., Ishak K. G. Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology. 1984 Mar;86(3):503–513. [PubMed] [Google Scholar]
  134. Loose D. S., Kan P. B., Hirst M. A., Marcus R. A., Feldman D. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest. 1983 May;71(5):1495–1499. doi: 10.1172/JCI110903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  135. Lutwick L. I., Rytel M. W., Yañez J. P., Galgiani J. N., Stevens D. A. Deep infections from Petriellidium boydii treated with miconazole. JAMA. 1979 Jan 19;241(3):272–273. [PubMed] [Google Scholar]
  136. Lyman C. A., Sugar A. M., Diamond R. D. Comparative activities of UK-49,858 and amphotericin B against Blastomyces dermatitidis infections in mice. Antimicrob Agents Chemother. 1986 Jan;29(1):161–162. doi: 10.1128/aac.29.1.161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  137. Marcano C., Feo M. Eficacia del econazol en embarazadas con candidiasis vulvo-vaginal. Mycopathologia. 1983 Feb 17;81(2):65–70. doi: 10.1007/BF00436981. [DOI] [PubMed] [Google Scholar]
  138. Marriott M. S., Baird J. R., Brammer K. W., Faulkner J. K., Halliwell G., Jevons S., Tarbit M. H. Tioconazole, a new imidazole-antifungal agent for the treatment of dermatomycoses. Antifungal and pharmacologic properties. Dermatologica. 1983;166 (Suppl 1):1–7. [PubMed] [Google Scholar]
  139. Mazabrey D., Nadal J., Seguela J. P., Linas M. D. Scanning and transmission electron microscopy: study of effects of econazole on Microsporum canis. Mycopathologia. 1985 Sep;91(3):151–157. doi: 10.1007/BF00446293. [DOI] [PubMed] [Google Scholar]
  140. Meunier-Carpentier F., Cruciani M., Klastersky J. Oral prophylaxis with miconazole or ketoconazole of invasive fungal disease in neutropenic cancer patients. Eur J Cancer Clin Oncol. 1983 Jan;19(1):43–48. doi: 10.1016/0277-5379(83)90396-6. [DOI] [PubMed] [Google Scholar]
  141. Mixich G., Thiele K. Ein Beitrag zur stereospezifischen Synthese von antimykotisch wirksamen Imidazolyloximäthern. Oxiconazol-nitrat (Sgd 301-76), ein neues Breitbandantimykotikum. Arzneimittelforschung. 1979;29(10):1510–1513. [PubMed] [Google Scholar]
  142. Mobacken H., Moberg S. Ketoconazole treatment of 13 patients with chronic mucocutaneous candidiasis. A prospective 3-year trial. Dermatologica. 1986;173(5):229–236. doi: 10.1159/000249259. [DOI] [PubMed] [Google Scholar]
  143. Morita T., Nozawa Y. Effects of antifungal agents on ergosterol biosynthesis in Candida albicans and Trichophyton mentagrophytes: differential inhibitory sites of naphthiomate and miconazole. J Invest Dermatol. 1985 Nov;85(5):434–437. doi: 10.1111/1523-1747.ep12277141. [DOI] [PubMed] [Google Scholar]
  144. Mosse M., Alric M. P., Berceaux M., Fourcine N., Salhi A. Etude comparative de l'activité fongistatique in vitro de l'omoconazole et de six autres imidazolés sur les levures. Pathol Biol (Paris) 1986 Jun;34(5 Pt 2):684–687. [PubMed] [Google Scholar]
  145. O'Neill East M., Henderson J. T., Jevons S. Tioconazole in the treatment of fungal infections of the skin. An international clinical research program. Dermatologica. 1983;166 (Suppl 1):20–33. doi: 10.1159/000249911. [DOI] [PubMed] [Google Scholar]
  146. Odds F. C., Abbott A. B., Pye G., Troke P. F. Improved method for estimation of azole antifungal inhibitory concentrations against Candida species, based on azole/antibiotic interactions. J Med Vet Mycol. 1986 Aug;24(4):305–311. doi: 10.1080/02681218680000461. [DOI] [PubMed] [Google Scholar]
  147. Odds F. C., Cheesman S. L., Abbott A. B. Antifungal effects of fluconazole (UK 49858), a new triazole antifungal, in vitro. J Antimicrob Chemother. 1986 Oct;18(4):473–478. doi: 10.1093/jac/18.4.473. [DOI] [PubMed] [Google Scholar]
  148. Odds F. C., Cheesman S. L., Abbott A. B. Suppression of ATP in Candida albicans by imidazole and derivative antifungal agents. Sabouraudia. 1985 Dec;23(6):415–424. [PubMed] [Google Scholar]
  149. Odds F. C., Cockayne A., Hayward J., Abbott A. B. Effects of imidazole- and triazole-derivative antifungal compounds on the growth and morphological development of Candida albicans hyphae. J Gen Microbiol. 1985 Oct;131(10):2581–2589. doi: 10.1099/00221287-131-10-2581. [DOI] [PubMed] [Google Scholar]
  150. Odds F. C. Laboratory evaluation of antifungal agents: a comparative study of five imidazole derivatives of clinical importance. J Antimicrob Chemother. 1980 Nov;6(6):749–761. doi: 10.1093/jac/6.6.749. [DOI] [PubMed] [Google Scholar]
  151. Odds F. C., MacDonald F. Persistence of miconazole in vaginal secretions after single applications. Implications for the treatment of vaginal candidosis. Br J Vener Dis. 1981 Dec;57(6):400–401. doi: 10.1136/sti.57.6.400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  152. Odds F. C., Milne L. J., Gentles J. C., Ball E. H. The activity in vitro and in vivo of a new imidazole antifungal, ketoconazole. J Antimicrob Chemother. 1980 Jan;6(1):97–104. doi: 10.1093/jac/6.1.97. [DOI] [PubMed] [Google Scholar]
  153. Odds F. C., Webster C. E., Abbott A. B. Antifungal relative inhibition factors: BAY l-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents. J Antimicrob Chemother. 1984 Aug;14(2):105–114. doi: 10.1093/jac/14.2.105. [DOI] [PubMed] [Google Scholar]
  154. Ogata M., Matsumoto H., Hamada Y., Takehara M., Tawara K. 1-[1-[2-[(3-Chlorobenzyl)oxy]phenyl]vinyl]-1H-imidazole hydrochloride, a new potent antifungal agent. J Med Chem. 1983 May;26(5):768–770. doi: 10.1021/jm00359a026. [DOI] [PubMed] [Google Scholar]
  155. Oji E. O., Clayton Y. M. The role of econazole in the management of oculomycosis. Int Ophthalmol. 1982 Feb;4(3):137–142. doi: 10.1007/BF00161903. [DOI] [PubMed] [Google Scholar]
  156. Osumi M., Yamada N., Okada J., Yamaguchi H., Hiratani T., Plempel M. The effect of bifonazole on the structure of Trichophyton. Arzneimittelforschung. 1983;33(10):1484–1491. [PubMed] [Google Scholar]
  157. Palou de Fernandez E., Patino M. M., Graybill J. R., Tarbit M. H. Treatment of cryptococcal meningitis in mice with fluconazole. J Antimicrob Chemother. 1986 Aug;18(2):261–270. doi: 10.1093/jac/18.2.261. [DOI] [PubMed] [Google Scholar]
  158. Perfect J. R., Durack D. T. Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. J Antimicrob Chemother. 1985 Jul;16(1):81–86. doi: 10.1093/jac/16.1.81. [DOI] [PubMed] [Google Scholar]
  159. Perfect J. R., Savani D. V., Durack D. T. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. Antimicrob Agents Chemother. 1986 Apr;29(4):579–583. doi: 10.1128/aac.29.4.579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  160. Plempel M. Antimycotic activity of BAY N 7133 in animal experiments. J Antimicrob Chemother. 1984 May;13(5):447–463. doi: 10.1093/jac/13.5.447. [DOI] [PubMed] [Google Scholar]
  161. Plempel M., Bartmann K., Büchel K. H., Regel E. Experimentelle Befunde über ein neues, oral wirksames Antimykotikum mit breiten Wirkungsspektrum. Dtsch Med Wochenschr. 1969 Jun 27;94(26):1356–passim. doi: 10.1055/s-0028-1111223. [DOI] [PubMed] [Google Scholar]
  162. Plempel M. On the action kinetics of clotrimazole. Chemotherapy. 1982;28 (Suppl 1):22–31. doi: 10.1159/000238148. [DOI] [PubMed] [Google Scholar]
  163. Plempel M., Regel E., Büchel K. H. Antimycotic efficacy of bifonazole in vitro and in vivo. Arzneimittelforschung. 1983;33(4):517–524. [PubMed] [Google Scholar]
  164. Polak-Wyss A., Lengsfeld H., Oesterhelt G. Effect of oxiconazole and Ro 14-4767/002 on sterol pattern in Candida albicans. Sabouraudia. 1985 Dec;23(6):433–441. doi: 10.1080/00362178585380631. [DOI] [PubMed] [Google Scholar]
  165. Polak A. Antifungal activity of four antifungal drugs in the cutaneous retention time test. Sabouraudia. 1984;22(6):501–503. doi: 10.1080/00362178485380781. [DOI] [PubMed] [Google Scholar]
  166. Polak A., Dixon D. M. Fungistatic and fungicidal effects of amphotericin B, ketoconazole and fluconazole (UK 49,858) against histoplasma capsulatum in vitro and in vivo. Mykosen. 1987 Apr;30(4):186–194. doi: 10.1111/j.1439-0507.1987.tb03967.x. [DOI] [PubMed] [Google Scholar]
  167. Polak A. Oxiconazole, a new imidazole derivative. Evaluation of antifungal activity in vitro and in vivo. Arzneimittelforschung. 1982;32(1):17–24. [PubMed] [Google Scholar]
  168. Polak A., Scholer H. J., Wall M. Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice. Chemotherapy. 1982;28(6):461–479. doi: 10.1159/000238138. [DOI] [PubMed] [Google Scholar]
  169. Pont A., Williams P. L., Loose D. S., Feldman D., Reitz R. E., Bochra C., Stevens D. A. Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med. 1982 Sep;97(3):370–372. doi: 10.7326/0003-4819-97-3-370. [DOI] [PubMed] [Google Scholar]
  170. Preusser H. J., Rostek H. Econazole effects on Trichophyton rubrum and Candida albicans--electron microscopic and cytochemical studies. Mykosen Suppl. 1978;1:314–321. [PubMed] [Google Scholar]
  171. Pye G. W., Marriott M. S. Inhibition of sterol C14 demethylation by imidazole-containing antifungals. Sabouraudia. 1982 Dec;20(4):325–329. doi: 10.1080/00362178285380461. [DOI] [PubMed] [Google Scholar]
  172. ROBINSON H. J., PHARES H. F., GRAESSLE O. E. ANTIMYCOTIC PROPERTIES OF THIABENDAZOLE. J Invest Dermatol. 1964 Jun;42:479–482. doi: 10.1038/jid.1964.101. [DOI] [PubMed] [Google Scholar]
  173. Rajfer J., Sikka S. C., Rivera F., Handelsman D. J. Mechanism of inhibition of human testicular steroidogenesis by oral ketoconazole. J Clin Endocrinol Metab. 1986 Nov;63(5):1193–1198. doi: 10.1210/jcem-63-5-1193. [DOI] [PubMed] [Google Scholar]
  174. Reingold A. L., Lu X. D., Plikaytis B. D., Ajello L. Systemic mycoses in the United States, 1980-1982. J Med Vet Mycol. 1986 Dec;24(6):433–436. [PubMed] [Google Scholar]
  175. Richardson K., Brammer K. W., Marriott M. S., Troke P. F. Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes. Antimicrob Agents Chemother. 1985 May;27(5):832–835. doi: 10.1128/aac.27.5.832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  176. Ritter W., Plempel M. Pharmacokinetics of the oral triazole antimycotic vibunazole in animals. J Antimicrob Chemother. 1984 Sep;14(3):243–252. doi: 10.1093/jac/14.3.243. [DOI] [PubMed] [Google Scholar]
  177. Roberts D. T., Adriaans B., Gentles J. C. A comparative study of once daily bifonazole cream versus twice daily miconazole cream in the treatment of tinea pedis. Mykosen. 1985 Nov;28(11):550–552. [PubMed] [Google Scholar]
  178. Rogers T. E., Galgiani J. N. Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother. 1986 Sep;30(3):418–422. doi: 10.1128/aac.30.3.418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  179. Rohde-Werner H. Topical tioconazole versus systemic ketoconazole treatment of vaginal candidiasis. J Int Med Res. 1984;12(5):298–302. doi: 10.1177/030006058401200506. [DOI] [PubMed] [Google Scholar]
  180. Rohwedder J. J., Archer G. Pulmonary sporotrichosis: Treatment with miconazole. Am Rev Respir Dis. 1976 Aug;114(2):403–406. doi: 10.1164/arrd.1976.114.2.403. [DOI] [PubMed] [Google Scholar]
  181. Rumler W., Heins S., Heins J. Beziehungen zwischen Antimykotikum-Konzentration und Kontaktzeit bei der Wirkung von 5-Fluorzytosin, Bifonazol und BAY N 7133 auf Candida albicans. Mykosen. 1984 Sep;27(9):436–442. [PubMed] [Google Scholar]
  182. Rumler W., Heins S. Konzentrations-Kontaktzeit-Beziehungen bei der Wirkung von Clotrimazol auf Candida albicans. Mykosen. 1983 Jun;26(6):293–297. doi: 10.1111/j.1439-0507.1983.tb03213.x. [DOI] [PubMed] [Google Scholar]
  183. Rutgeerts L., Verhaegen H. Intravenous miconazole in the treatment of chronic esophageal candidiasis. Gastroenterology. 1977 Feb;72(2):316–318. [PubMed] [Google Scholar]
  184. Ryley J. F., Wilson R. G., Barrett-Bee K. J. Azole resistance in Candida albicans. Sabouraudia. 1984;22(1):53–63. [PubMed] [Google Scholar]
  185. Santen R. J., Van den Bossche H., Symoens J., Brugmans J., DeCoster R. Site of action of low dose ketoconazole on androgen biosynthesis in men. J Clin Endocrinol Metab. 1983 Oct;57(4):732–736. doi: 10.1210/jcem-57-4-732. [DOI] [PubMed] [Google Scholar]
  186. Savani D. V., Perfect J. R., Cobo L. M., Durack D. T. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother. 1987 Jan;31(1):6–10. doi: 10.1128/aac.31.1.6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  187. Schaffner A., Frick P. G. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. J Infect Dis. 1985 May;151(5):902–910. doi: 10.1093/infdis/151.5.902. [DOI] [PubMed] [Google Scholar]
  188. Schär G., Kayser F. H., Dupont M. C. Antimicrobial activity of econazole and miconazole in vitro and in experimental candidiasis and aspergillosis. Chemotherapy. 1976;22(3-4):211–220. doi: 10.1159/000221928. [DOI] [PubMed] [Google Scholar]
  189. Schürmeyer T., Nieschlag E. Effect of ketoconazole and other imidazole fungicides on testosterone biosynthesis. Acta Endocrinol (Copenh) 1984 Feb;105(2):275–280. doi: 10.1530/acta.0.1050275. [DOI] [PubMed] [Google Scholar]
  190. Scott E. M., Gorman S. P., McGrath S. J. Inhibition of hyphal development in Trichophyton mentagrophytes arthroconidia by ketoconazole and miconazole. J Antimicrob Chemother. 1985 Apr;15(4):405–415. doi: 10.1093/jac/15.4.405. [DOI] [PubMed] [Google Scholar]
  191. Scott E. M., Gorman S. P., Millership J. S., Wright L. R. Effect of miconazole and clotrimazole on K+ release and inhibition of ergosterol biosynthesis in Trichophyton mentagrophytes and related ultrastructural observations. J Antimicrob Chemother. 1986 Apr;17(4):423–432. doi: 10.1093/jac/17.4.423. [DOI] [PubMed] [Google Scholar]
  192. Shadomy S., Dixon D. M., May R. A comparison of bifonazole (BAY H 4502) with clotrimazole in vitro. Sabouraudia. 1982 Dec;20(4):313–323. [PubMed] [Google Scholar]
  193. Shadomy S., Espinel-Ingroff A., Kerkering T. M. In-vitro studies with four new antifungal agents: BAY n 7133, bifonazole (BAY h 4502), ICI 153,066 and Ro 14-4767/002. Sabouraudia. 1984;22(1):7–15. doi: 10.1080/00362178485380041. [DOI] [PubMed] [Google Scholar]
  194. Shadomy S., Espinel-Ingroff A., Tartaglione T. A., Dismukes W. E. Treatment of systemic mycoses with ketoconazole: studies of ketoconazole serum levels. Mykosen. 1986 May;29(5):195–209. [PubMed] [Google Scholar]
  195. Shadomy S. In vitro antifungal activity of clotrimazole (Bay b 5097). Infect Immun. 1971 Aug;4(2):143–148. doi: 10.1128/iai.4.2.143-148.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  196. Shadomy S., White S. C., Yu H. P., Dismukes W. E. Treatment of systemic mycoses with ketoconazole: in vitro susceptibilities of clinical isolates of systemic and pathogenic fungi to ketoconazole. J Infect Dis. 1985 Dec;152(6):1249–1256. doi: 10.1093/infdis/152.6.1249. [DOI] [PubMed] [Google Scholar]
  197. Shepp D. H., Klosterman A., Siegel M. S., Meyers J. D. Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment. J Infect Dis. 1985 Dec;152(6):1257–1263. doi: 10.1093/infdis/152.6.1257. [DOI] [PubMed] [Google Scholar]
  198. Shigematsu M. L., Uno J., Arai T. Effect of ketoconazole on isolated mitochondria from Candida albicans. Antimicrob Agents Chemother. 1982 Jun;21(6):919–924. doi: 10.1128/aac.21.6.919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  199. Slotman G. J., Burchard K. W. Ketoconazole prevents Candida sepsis in critically ill surgical patients. Arch Surg. 1987 Feb;122(2):147–151. doi: 10.1001/archsurg.1987.01400140029002. [DOI] [PubMed] [Google Scholar]
  200. Sobel J. D., Muller G. Comparison of itraconazole and ketoconazole in the treatment of experimental candidal vaginitis. Antimicrob Agents Chemother. 1984 Aug;26(2):266–267. doi: 10.1128/aac.26.2.266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  201. Sobel J. D., Muller G. Comparison of ketoconazole, Bay N7133, and Bay L9139 in the treatment of experimental vaginal candidiasis. Antimicrob Agents Chemother. 1983 Sep;24(3):434–436. doi: 10.1128/aac.24.3.434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  202. Sobel J. D. Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. N Engl J Med. 1986 Dec 4;315(23):1455–1458. doi: 10.1056/NEJM198612043152305. [DOI] [PubMed] [Google Scholar]
  203. Sonino N. The endocrine effects of ketoconazole. J Endocrinol Invest. 1986 Aug;9(4):341–347. doi: 10.1007/BF03346939. [DOI] [PubMed] [Google Scholar]
  204. Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med. 1987 Sep 24;317(13):812–818. doi: 10.1056/NEJM198709243171307. [DOI] [PubMed] [Google Scholar]
  205. States B., Palmieri M. J., Segal S. Uptake of proline in cultured cells from patients with Lowe's syndrome. Biochem Biophys Res Commun. 1982 Nov 30;109(2):428–433. doi: 10.1016/0006-291x(82)91739-9. [DOI] [PubMed] [Google Scholar]
  206. Stenderup A., Schønheyder H. Mycoses complicating AIDS. Microbiol Sci. 1984 Dec;1(9):219–223. [PubMed] [Google Scholar]
  207. Stevens D. A., Levine H. B., Deresinski S. C. Miconazole in coccidiodomycosis. II. Therapeutic and pharmacologic studies in man. Am J Med. 1976 Feb;60(2):191–202. doi: 10.1016/0002-9343(76)90428-9. [DOI] [PubMed] [Google Scholar]
  208. Stevens D. A. Miconazole in the treatment of coccidioidomycosis. Drugs. 1983 Oct;26(4):347–354. doi: 10.2165/00003495-198326040-00004. [DOI] [PubMed] [Google Scholar]
  209. Stevens D. Miconazole in the treatment of systemic fungal infections. Am Rev Respir Dis. 1977 Nov;116(5):801–806. doi: 10.1164/arrd.1977.116.5.801. [DOI] [PubMed] [Google Scholar]
  210. Stüttgen G., Bauer E. Bioavailability, skin- and nailpenetration of topically applied antimycotics. Mykosen. 1982 Feb;25(2):74–80. doi: 10.1111/j.1439-0507.1982.tb02721.x. [DOI] [PubMed] [Google Scholar]
  211. Stüttgen G., Bauer E. Permeation von markiertem Oxiconazol. Vergleich der autoradiographischen mit der Horizontalschnitt-Technik an menschlicher Haut. Mykosen. 1985 Mar;28(3):138–147. [PubMed] [Google Scholar]
  212. Sud I. J., Feingold D. S. Heterogeneity of action of mechanisms among antimycotic imidazoles. Antimicrob Agents Chemother. 1981 Jul;20(1):71–74. doi: 10.1128/aac.20.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  213. Sud I. J., Feingold D. S. Mechanisms of action of the antimycotic imidazoles. J Invest Dermatol. 1981 Jun;76(6):438–441. doi: 10.1111/1523-1747.ep12521036. [DOI] [PubMed] [Google Scholar]
  214. Sung J. P., Grendahl J. G., Levine H. B. Intravenous and intrathecal miconazole therapy for systemic mycoses. West J Med. 1977 Jan;126(1):5–13. [PMC free article] [PubMed] [Google Scholar]
  215. Tanenbaum L., Anderson C., Rosenberg M. J., Akers W. 1% sulconazole cream v 2% miconazole cream in the treatment of tinea versicolor. A double-blind, multicenter study. Arch Dermatol. 1984 Feb;120(2):216–219. [PubMed] [Google Scholar]
  216. Tanenbaum L., Anderson C., Rosenberg M. J., Howard W., McDaniel W., Neimanis A., Ryan M. E., Perez R. Sulconazole nitrate 1.0 percent cream: a comparison with miconazole in the treatment of tinea pedis and tinea cruris/corporis. Cutis. 1982 Jul;30(1):105-7, 115, 118. [PubMed] [Google Scholar]
  217. Taylor F. R., Rodriguez R. J., Parks L. W. Relationship between antifungal activity and inhibition of sterol biosynthesis in miconazole, clotrimazole, and 15-azasterol. Antimicrob Agents Chemother. 1983 Apr;23(4):515–521. doi: 10.1128/aac.23.4.515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  218. Thienpont D., Van Cutsem J., Van Gerven F., Heeres J., Janssen P. A. Ketoconazole -- a new broad spectrum orally active antimycotic. Experientia. 1979 May 15;35(5):606–607. doi: 10.1007/BF01960348. [DOI] [PubMed] [Google Scholar]
  219. Thienpont D., Van Cutsem J., Van Nueten J. M., Niemegeers C. J., Marsboom R. Bilogical and toxicological properties of econazole, a broad-spectrum antimycotic. Arzneimittelforschung. 1975 Feb;25(2):224–230. [PubMed] [Google Scholar]
  220. Tolman E. L., Isaacson D. M., Rosenthale M. E., McGuire J. L., Van Cutsem J., Borgers M., Van den Bossche H. Anticandidal activities of terconazole, a broad-spectrum antimycotic. Antimicrob Agents Chemother. 1986 Jun;29(6):986–991. doi: 10.1128/aac.29.6.986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  221. Trachtenberg J. Ketoconazole therapy in advanced prostatic cancer. J Urol. 1984 Jul;132(1):61–63. doi: 10.1016/s0022-5347(17)49464-x. [DOI] [PubMed] [Google Scholar]
  222. Troke P. F., Andrews R. J., Brammer K. W., Marriott M. S., Richardson K. Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice. Antimicrob Agents Chemother. 1985 Dec;28(6):815–818. doi: 10.1128/aac.28.6.815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  223. Troke P. F., Andrews R. J., Marriott M. S., Richardson K. Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice. J Antimicrob Chemother. 1987 May;19(5):663–670. doi: 10.1093/jac/19.5.663. [DOI] [PubMed] [Google Scholar]
  224. Täuber U. Availability of isoconazole in human skin after dermal application as free base and as nitrate in vitro. Arzneimittelforschung. 1987 Apr;37(4):461–463. [PubMed] [Google Scholar]
  225. Täuber U., Rach P., Lachnit U. Persistence of isoconazole in vaginal secretion after single application. Mykosen. 1984 Feb;27(2):97–101. doi: 10.1111/j.1439-0507.1984.tb02005.x. [DOI] [PubMed] [Google Scholar]
  226. Ueda A. K., Franco M., Fabio S. A., Prestes F. R. Ketoconazole in the treatment of experimental murine paracoccidioidomycosis. Mycopathologia. 1987 Apr;98(1):27–34. doi: 10.1007/BF00431014. [DOI] [PubMed] [Google Scholar]
  227. Uno J., Shigematsu M. L., Arai T. Primary site of action of ketoconazole on Candida albicans. Antimicrob Agents Chemother. 1982 Jun;21(6):912–918. doi: 10.1128/aac.21.6.912. [DOI] [PMC free article] [PubMed] [Google Scholar]
  228. Utz J. P. Chemotherapy for the systemic mycoses: the prelude to ketoconazole. Rev Infect Dis. 1980 Jul-Aug;2(4):625–632. doi: 10.1093/clinids/2.4.625. [DOI] [PubMed] [Google Scholar]
  229. Van Cutsem J. M., Thienpont D. Miconazole, a broad-spectrum antimycotic agent with antibacterial activity. Chemotherapy. 1972;17(6):392–404. doi: 10.1159/000220875. [DOI] [PubMed] [Google Scholar]
  230. Van Cutsem J., Fransen J., Janssen P. A. Therapeutic efficacy of itraconazole in systemic candidosis in guinea pigs. Chemotherapy. 1987;33(1):52–60. doi: 10.1159/000238475. [DOI] [PubMed] [Google Scholar]
  231. Van Cutsem J., Fransen J., Van Gerven F., Janssen P. A. Oral treatment with ketoconazole in systemic candidosis of guinea-pigs: microbiology, hematology and histopathology. Sabouraudia. 1985 Jun;23(3):189–198. doi: 10.1080/00362178585380291. [DOI] [PubMed] [Google Scholar]
  232. Van Cutsem J. The antifungal activity of ketoconazole. Am J Med. 1983 Jan 24;74(1B):9–15. doi: 10.1016/0002-9343(83)90508-9. [DOI] [PubMed] [Google Scholar]
  233. Van Cutsem J., Van Gerven F., Van de Ven M. A., Borgers M., Janssen P. A. Itraconazole, a new triazole that is orally active in aspergillosis. Antimicrob Agents Chemother. 1984 Oct;26(4):527–534. doi: 10.1128/aac.26.4.527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  234. Van Cutsem J., Van Gerven F., Zaman R., Janssen P. A. Terconazole - a new broad-spectrum antifungal. Chemotherapy. 1983;29(5):322–331. doi: 10.1159/000238215. [DOI] [PubMed] [Google Scholar]
  235. Van den Bossche H. Biochemical effects of miconazole on fungi. I. Effects on the uptake and or utilization of purines, pyrimidines, nucleosides, amino acids and glucose by Candida albicans. Biochem Pharmacol. 1974 Feb 15;23(4):887–899. doi: 10.1016/0006-2952(74)90220-2. [DOI] [PubMed] [Google Scholar]
  236. Vanden Bossche H. Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action. Curr Top Med Mycol. 1985;1:313–351. doi: 10.1007/978-1-4613-9547-8_12. [DOI] [PubMed] [Google Scholar]
  237. Veronese M., Barzaghi D., Bertoncini A. Antifungal activity of fenticonazole in experimental dermatomycosis and candidiasis. Arzneimittelforschung. 1981;31(12):2137–2139. [PubMed] [Google Scholar]
  238. Veronese M., Salvaterra M., Barzaghi D. Fenticonazole, a new imidazole derivative with antibacterial and antifungal activity. In vitro study. Arzneimittelforschung. 1981;31(12):2133–2137. [PubMed] [Google Scholar]
  239. Wade T. R., Jones H. E., Chanda J. J. Intravenous miconazole therapy of mycotic infections. Arch Intern Med. 1979 Jul;139(7):784–786. [PubMed] [Google Scholar]
  240. Wagner W. Vergleich der klinischen Wirksamkeit und Verträglichkeit von Oxiconazol nach 1 x täglicher Applikation mit der nach 2 x täglicher Applikation. Mykosen. 1986 Jun;29(6):280–284. [PubMed] [Google Scholar]
  241. Walker K. A., Braemer A. C., Hitt S., Jones R. E., Matthews T. R. 1-[4-(4-Chlorophenyl)-2-(2,6-dichlorophenylthio)-n-butyl]-1H-imidazole nitrate, a new potent antifungal agent. J Med Chem. 1978 Aug;21(8):840–843. doi: 10.1021/jm00206a028. [DOI] [PubMed] [Google Scholar]
  242. Walther M. Feldstudie Die Einmaltherapie von Vaginalmykosen mit isoconazolnitrat. Schweiz Rundsch Med Prax. 1982 Jan 26;71(4):152–156. [PubMed] [Google Scholar]
  243. Weisberg M. Treatment of vaginal candidiasis in pregnant women. Clin Ther. 1986;8(5):563–567. [PubMed] [Google Scholar]
  244. Wishart J. M., Gould P. W. Econazole treatment of fungal infections: an open trial. N Z Med J. 1981 Sep 23;94(692):226–227. [PubMed] [Google Scholar]
  245. Woestenborghs R., Lorreyne W., Heykants J. Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography. J Chromatogr. 1987 Jan 23;413:332–337. doi: 10.1016/0378-4347(87)80249-9. [DOI] [PubMed] [Google Scholar]
  246. Wood P. R., Tarbit M. H. Gas chromatographic method for the determination of fluconazole, a novel antifungal agent, in human plasma and urine. J Chromatogr. 1986 Nov 28;383(1):179–186. doi: 10.1016/s0378-4347(00)83458-1. [DOI] [PubMed] [Google Scholar]
  247. Yamaguchi H., Hiratani T., Plempel M. In vitro studies of a new imidazole antimycotic, bifonazole, in comparison with clotrimazole and miconazole. Arzneimittelforschung. 1983;33(4):546–551. [PubMed] [Google Scholar]
  248. Yamaguchi H., Hiratani T., Plempel M. In-vitro studies of a new oral azole antimycotic, BAY N 7133. J Antimicrob Chemother. 1983 Feb;11(2):135–149. doi: 10.1093/jac/11.2.135. [DOI] [PubMed] [Google Scholar]
  249. Yamaguchi H., Iwata K. Effect of two imidazole antimycotics, clotrimazole and miconazole on amino acid transport in Candida albicans. Sabouraudia. 1979 Sep;17(3):311–322. doi: 10.1080/00362177985380461. [DOI] [PubMed] [Google Scholar]
  250. Yap B. S., Bodey G. P. Oropharyngeal candidiasis treated with a troche form of clotrimazole. Arch Intern Med. 1979 Jun;139(6):656–657. [PubMed] [Google Scholar]
  251. Yozwiak M. L., Galgiani J. N. Itraconazole treatment of experimental systemic candidiasis in male rats. J Med Vet Mycol. 1987 Apr;25(2):125–126. doi: 10.1080/02681218780000171. [DOI] [PubMed] [Google Scholar]
  252. van Gulpen C., Kelder O., Mattie H., van der Meer J. W., van't Wout J. Pharmacokinetics of vibunazole (BAY n 7133) administered orally to healthy subjects. J Antimicrob Chemother. 1985 Jul;16(1):75–79. doi: 10.1093/jac/16.1.75. [DOI] [PubMed] [Google Scholar]
  253. van Rensburg C. E., Anderson R., Jooné G., van der Merwe M. F., Eftychis H. A. The effects of ketoconazole on cellular and humoral immune functions. J Antimicrob Chemother. 1983 Jan;11(1):49–55. doi: 10.1093/jac/11.1.49. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Microbiology Reviews are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES